Intelligent Bio Solutions
INBS

$1.79

18.26%

Market Cap: $5.58M

About: Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana.

Employees: 51

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

10.93% less ownership

Funds ownership: 21.04% [Q1] → 10.11% (-10.93%) [Q2]

43% less funds holding

Funds holding: 14 [Q1] → 8 (-6) [Q2]

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

76% less capital invested

Capital invested by funds: $2.52M [Q1] → $606K (-$1.91M) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for INBS.

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about INBS published over the past 30 days

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

- Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided a business update.

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Virtual Conference on September 18-19, 2024

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a leader in non-invasive drug testing technology, today announced that its management team will participate in the Sidoti Small-Cap Virtual Conference being held on September 18-19, 2024.

Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Virtual Conference on September 18-19, 2024

Penny stocks analysis: AITX, Intelligent Bio (INBS), Tonix (TNXP)

Penny stocks could see some more volatility in the coming months as the Federal Reserve starts cutting interest rates later this month. Historically, many traders tend to rotate to these companies when the Fed is cutting rates.

Penny stocks analysis: AITX, Intelligent Bio (INBS), Tonix (TNXP)

Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its progress toward completion of the clinical study plan required for its FDA 510(k) submission.

Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission

Intelligent Bio Solutions Inc. Reports 118% Year-Over-Year Growth in Customer Employee Base, Reaching an Estimated Total of 1.4 Million Employees

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a leader in non-invasive drug testing technology, today announced significant growth in its customer employee base, reporting a 118% fiscal year-over-year increase in the estimated total number of employees across its customer base.

Intelligent Bio Solutions Inc. Reports 118% Year-Over-Year Growth in Customer Employee Base, Reaching an Estimated Total of 1.4 Million Employees

Intelligent Bio Solutions Inc. Achieves Major Milestone with Over 1,000 Installed Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a leading innovator in non-invasive drug testing technology, today announced the installation of over 1,000 Intelligent Fingerprinting Drug Screening Readers with customers as of June 30, 2024. This achievement marks a significant milestone for INBS, underscoring the growing demand for the Company's advanced drug screening technology.

Intelligent Bio Solutions Inc. Achieves Major Milestone with Over 1,000 Installed Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Intelligent Bio Solutions Inc. Highlights Growing Need for Drug Testing Solutions in Key Industries

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing prevalence of on-the-job drug use across critical sectors such as construction, manufacturing, transport and warehousing, mining, and automotive. As the need for robust drug testing solutions intensifies, we believe that our company is positioned to lead the way in providing innovative, non-invasive drug testing technologies.

Intelligent Bio Solutions Inc. Highlights Growing Need for Drug Testing Solutions in Key Industries

Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway

Intelligent Bio Solutions Inc. (INBS) partners with CenExel to perform a method comparison clinical study as part of the Company's FDA clinical study plan.

Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway

Intelligent Bio Solutions Inc. Announces QabasTech as Exclusive Distributor in Saudi Arabia

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced QabasTech (“Qabas”) as its exclusive distributor in Saudi Arabia. This partnership marks further growth for INBS in the country, aligning with its ambitious infrastructure projects and commitment to improving public safety.

Intelligent Bio Solutions Inc. Announces QabasTech as Exclusive Distributor in Saudi Arabia

See News Rankings